Baird lowered the firm’s price target on AdaptHealth (AHCO) to $14 from $16 and keeps an Outperform rating on the shares. The firm said the company is delivering in most categories, with strong BS/CF improvement, and overall operational improvement, except for Diabetes. The company’s diabetes business is bad, and it is getting a major overhaul.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AHCO: